Introduction
Diffuse panbronchiolitis (DPB) is a chronic inflammation of the respiratory bronchioles (1 , 2) ; it is also termed bronchiolitis and peribronchiolitis.
The condition is diagnosed radiographically by the presence ofmicronodular shadows that are diffusely disseminated throughout both lungs. Although the prognosis of DPBis poor, Kudoh et al (3) reported that the long-term administration of low doses of erythromycin, a 14-membered ring macrolide, is highly effective in improving the clinical symptoms, pulmonary dysfunction, and hypoxia in this disorder (4) (5) (6) . These benefits were obtained without the eradication of bacteria from the sputum such as Pseudomonasaeruginosa, which is resistant to erythromycin.
While the mechanisms that underlie the efficacy of erythromycin in treating DPBare unknown, findings suggest that they depend on other than microbicidal activity. Recent reports have indicated that polymorphonuclear leukocytes (PMNs) may be involved in the deterioration of patients with DPBby producing a persistent, excessive influx of PMNsinto the lung. Such cells produce a variety of oxidants and proteolytic enzymes, which ultimately damage the lung parenchyma (7-1 0). Erythromycin inhibits PMNchemotaxis (1 1). Treatment with this antibiotic reduces the amount of PMNand PMN-derivedelastolytic-like activity in bronchoalveolar lavage fluid ( 1 2) . Two new relatives of erythromycin, roxithromycin and clarithromycin, also 14-memberedring macrolides, achieve higher serum levels than erythromycin and have longerhalf-lives ( 1 3). The 1 6-membered ring macrolide, josamycin however, is ineffective in treating DPB (14) .
Weconducted this study to determine whether erythromycin and its two derivatives would produce similar benefits in patients with DPBand bronchiectasis (BE). We also tried to determine how these antibiotics, as well as josamycin, act in these diseases by conducting an in vitro study to compare PMN activities including chemotaxis, phagocytosis , and oxygen radical generation.
Materials and Methods

Clinical profile of patients
Westudied 74 patients with chronic lower respiratory tract infection, including DPBand BE. The clinical background of each patient is summarized in Table 1 . Twenty patients were diagnosed as having DPBfrom the examination of open lung biopsy specimens. In another 14 patients with computed tomographic (CT) findings compatible with DPB, noninvasive diagnostic procedures confirmed the presence of DPBbased on the criteria proposed by the Japanese Ministry of Health and Welfare (1) . Forty patients had BE that had been diagnosed on the basis of CT or bronchography. All patients demonstrated the symptomsof DPBor BE, i.e., chronic cough, purulent sputum, and dyspnea on exertion (DOE). Moist or dry rales were also heard on auscultation. Each patient received one of the following macrolide antibiotics orally each day for at least two months: erythromycin (400 or 600 mg/day), roxithromycin ( 150 or 300 mg/day), orclarithromycin (200 or400 mg/day). Of the three groups, the DPBpatients given erythromycin had the longest duration of symptoms, and their condition was judged to be more severe, based on DOEgrade, results of pulmonary function tests and ofPaO2analyses. Chest X-rays of all cases of DPBshowed hyperinflation, diffuse micronodular shadows, and peribronchial thickening in both lungs. at a concentration of2.5xl07/ml in HBSSin the presence of200 jllI ofautologous plasma, giving a PMN/bead ratio of 1/1 0. After incubation at 37°C for 60 minutes and three washings to separate the nonphagocytotic spheres, the number of phagocytotic PMNswas evaluated with a flow cytometer (EPICS-PROFILE, Coulter Corp., Miami, FL). The rate ofphagocytosis was obtained by dividing the number ofPMNs that had phagocytized one or more spheres by the total number of PMNs.
In vitro effect of macrolides on human PMNs Samples of peripheral venous blood were obtained from six healthy volunteers, and PMNs were isolated as previously described. Next, each macrolide, i.e. erythromycin (Sigma Chemical Co.), roxithromycin (Eisai Co., Ltd., Tokyo), clarithromycin (Dainabot Co., Ltd., Osaka), and josamycin (Wako Pure Chemical Industries, Ltd., Osaka) was dissolved in a0. 1 M CH3COONabuffer, pH 5.0, ataconcentration of 10mg/ ml, then diluted with HBSSto give a final concentration of 100 to 0. 1 |ig/ml. For the control, the CH3COONa buffer without an antibiotic was used.
PMNswere preincubated with each antibiotic for 30 minutes at 37°C. The effect on chemotaxis and phagocytosis was examined as described above. The generation of oxygen radicals was measured by a previously described method of chemiluminescence using a cypridina luciferin analog, 2-methyl-6-phenyl-3 ,7-dihydroimidazo[ l ,2-a]pyrazin-3-one (CLA) (Tokyo Kasei Kogyo Co., Ltd., Tokyo) (16). In brief, PMNs, lxl05/ml, were incubated with 5 |iM of CLAand the given concentration of each antibiotic in 1 ml HBSS. The reaction was triggered by adding FMLPas a stimulus at a final concentration of 10~7 M. The amount of oxygen radicals generated was measured according to the greatest increase in light intensity using a luminescence reader (BLR-301 , Aloka Co., Ltd., Tokyo).
Statistical analysis
Results are expressed as a mean±SE.Analysis used the Student's t-test or ANOVA. A level ofp<0.05 was considered as statistically significant.
Results
Clinical efficacy
With antibiotic treatment, cough and sputum ceased in most of the patients with DPB, and chest x-ray findings improved in some cases. Table 2 shows the change in grade of DOE, pulmonary function tests, and arterial blood gas analysis before and after antibiotic treatment. All values improved significantly in patients who received erythromycin (p<0.05). Patients administered roxithromycin or clarithromycin showed a trend toward improvement in each parameter. The efficacy of erythromycin, roxithromycin, and clarithromycin in DPB was 1 9/24 (79%), 6/7 (86%), and 2/3 (67%), respectively. Chemotaxis and phagocytosis before vs. after roxithromycin th erapy
The effects on PMNchemotaxis and phagocytosis in the patients with DPBor BE who were administered roxithromycin are shown in Fig. 1 . While chemotaxis was significantly re- duced in all five patients who had responded to roxithromycin (p<0.05), overall, there were no significant changes in the rate of phagocytosis before vs. after the therapy.
In vitro effect of macrolides on human PMNs Figure 2 illustrates the effects of each of the four macrolides on chemotaxis of PMNsobtained from six healthy volunteers.
Each antibiotic given at concentrations of 1 and 10 Jig/ml, suppressed the chemotaxis induced by FMLPby approximately 1 0% vs. controls. A concentration of 100 |ig/ml ofroxithromycin tended to reduced the response, while that same dose of each of the other three antibiotics did not alter chemotactic activity. Differences were not statistically significant. In contrast, the phagocytosis of PMNs pretreated with a macrolide was not affected by any of the concentrations tested (Fig. 3) . The effects of each macrolide on the FMLP-activated PMNs are shown in Fig. 4 . Erythromycin, clarithromycin, and josamycin each produced a dose-dependent increase in chemi- Polymorphonuclear neutrophils had been preincubated with each agent for 30 minutes at 37°C. Data are mean±SE(n=4).
luminescence that was statistically significant at concentrations of 10 and 100 jug/ml. Atconcentrations of 10 and 100 [ig/ml, the mean increases were 8% and 21% for erythromycin, 15% and 38% for clarithromycin, and 19% and 42% for josamycin, respectively (p<0.05). However, roxithromycin at concentrations of 10 and 100 |Hg/ml, and any antibiotic at a concentration of 1 |Lig/ml caused no significant change.
Discussion
To date, there is no agreement on the treatment to prevent the deterioration of a patient with chronic respiratory tract infection. While DPBhas a poor prognosis, the long-term administration ofa low dose oferythromycin can provide benefit (3) (4) (5) (6) . Interestingly, such a low dose oferythromycin rarely eradicates pathogens from the lower respiratory tract, unlike the conventional doses used in treating an acute exacerbation. Erythromycin is effective even in cases with colonization ofP aeruginosa, which is insensitive to this antibiotic. In one study, the levels of erythromycin in the serum or sputum of a response group vs. a nonresponse group did not differ (5). These findings suggest that the efficacy of erythromycin in DPBmay correlate with mechanisms unrelated to its microbicidal activity. Wesought to determine whether other 14-memberedmacrolides would be as efficacious as erythromycin in treating patients with DPBor BE.
Results indicated that the long-term administration of roxithromycin, clarithromycin, and erythromycin were each effective in treating DPB. The long-term administration of roxithromycin and clarithromycin each improved the clinical symptoms of BE.
PMN chemotaxis was significantly reduced following roxithromycin therapy. Similar to the results previously reported with erythromycin therapy (17), the suppression of chemotaxis appeared to be related to an improvement in the patient' s condition. In the in vitro study,josamycin had the same inhibitory effect on the chemotaxis of PMNs as erythromycin, roxithromycin, and clarithromycin at the concentrations tested, even though josamycin is reportedly ineffective in treating DPB. Erythromycin, clarithromycin, and josamycin potentiated the generation of oxygen radicals by PMN,whereas roxithromycin had no effect. Thus, the ability to potentiate the generation of oxygen radicals was inconsistently observed with these 14-membered ring macrolides. The effects of several macrolides on chemotaxis and on the generation of oxygen radicals by PMNhave been studied in vivo and in vitro, with similar results reported (1 8-23 ). Thus, it does not appear that the effectiveness of these 14-membered ring macrolides for treating DPBand BE can be explained by a direct effect on the chemotaxis, phagocytosis, and generation of oxygen radicals by PMNs. However, erythromycin exerts someeffect on PMNs,as a neutrophil chemotactic factor is reportedly reduced in the bronchoalveolar lavage fluid of patients with DPBfollowing its administration (24) . Erythromycin suppresses the secretion of mucusand water fromthe airway membranes (25, 26) , and inhibits activated T lymphocytes (27) , as well as enhances the proliferation and differentiation of the progenitors of macrophages (28) . Future studies of the immunomodulating effects of the 14-membered ring macrolides should focus on the mechanismof the efficacy in treating DPB. Their effectiveness whengiven at low doses for treating chronic respiratory tract infection appears to not be directly related to PMNchemotaxis, phagocytosis, or the generation of oxygen radicals.
